21.03.2023 03:59:00

ROSEN, A RANKED AND LEADING FIRM, Encourages Veradigm Inc. Investors to Inquire About Class Action Investigation - MDRX

NEW YORK, March 20, 2023 /PRNewswire/ --

Rosen Law Firm, P.A. Logo

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Veradigm Inc. (NASDAQ: MDRX) resulting from allegations that Veradigm may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Veradigm securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=12772 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On February 28, 2023, Veradigm disclosed that it "detected certain internal control failures related to revenue recognition that have occurred over the prior six quarters, resulting in a mis-statement to reported revenues during those periods." As a result, the Company reported that it expects "a reduction in revenue from continuing operations of approximately $20 million dollars in the aggregate from what it otherwise reported since the 3rd quarter of 2021 and expected to report for the 4th quarter of 2022." The Company added that it is "continuing to evaluate the materiality of the mis-statement to determine if the full amount of this adjustment will flow through in the 4th quarter of 2022 or if prior periods will also require adjustment." As a result, Veradigm revised its 2023 guidance downward and announced that it would not be filing its 2022 annual report on time.

On this news, Veradigm's stock price fell $2.12 per share, or 12%, to close at $14.49 per share on March 1, 2023.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      lrosen@rosenlegal.com
      pkim@rosenlegal.com
      cases@rosenlegal.com
      www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/rosen-a-ranked-and-leading-firm-encourages-veradigm-inc-investors-to-inquire-about-class-action-investigation--mdrx-301776764.html

SOURCE Rosen Law Firm, P.A.

Nachrichten zu Allscripts Healthcare Solutions Incmehr Nachrichten

26.09.24
NASDAQ Composite Index-Titel Allscripts Healthcare Solutions-Aktie: So viel hätte eine Investition in Allscripts Healthcare Solutions von vor einem Jahr gekostet (finanzen.at)
19.09.24
NASDAQ Composite Index-Papier Allscripts Healthcare Solutions-Aktie: So viel Verlust wäre bei einem Investment in Allscripts Healthcare Solutions von vor 10 Jahren angefallen (finanzen.at)
12.09.24
NASDAQ Composite Index-Titel Allscripts Healthcare Solutions-Aktie: So viel hätten Anleger mit einem Investment in Allscripts Healthcare Solutions von vor 5 Jahren verloren (finanzen.at)
05.09.24
NASDAQ Composite Index-Papier Allscripts Healthcare Solutions-Aktie: So viel hätten Anleger an einem Allscripts Healthcare Solutions-Investment von vor 3 Jahren verloren (finanzen.at)
29.08.24
NASDAQ Composite Index-Papier Allscripts Healthcare Solutions-Aktie: So viel Verlust hätte eine Allscripts Healthcare Solutions-Investition von vor einem Jahr eingebracht (finanzen.at)
22.08.24
NASDAQ Composite Index-Wert Allscripts Healthcare Solutions-Aktie: So viel hätte eine Investition in Allscripts Healthcare Solutions von vor 10 Jahren gekostet (finanzen.at)
15.08.24
NASDAQ Composite Index-Wert Allscripts Healthcare Solutions-Aktie: So viel hätten Anleger an einem Allscripts Healthcare Solutions-Investment von vor 5 Jahren verdient (finanzen.at)
08.08.24
NASDAQ Composite Index-Titel Allscripts Healthcare Solutions-Aktie: So viel Verlust hätte ein Investment in Allscripts Healthcare Solutions von vor 3 Jahren eingebracht (finanzen.at)

Analysen zu Allscripts Healthcare Solutions Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Allscripts Healthcare Solutions Inc 9,20 4,55% Allscripts Healthcare Solutions Inc